Neuronetics Receives FDA Clearance For Transcranial Magnetic Stimulation System For Depression
About 50% of the 13.9 million people undergoing treatment in the US for major depressive disorder have anxious depression, which represents a large market opportunity for Neuronetics, according to an analyst.
